FTPP
Also known as: Fat Targeted Proapoptotic Peptide, Adipose-targeting peptide
FTPP (Fat Targeted Proapoptotic Peptide) is an experimental peptide designed to selectively target adipose tissue and induce fat cell death through apoptosis. This targeted approach aims to reduce fat deposits without affecting other tissues.
FTPP is a 2,847 Da research peptide. FTPP (Fat Targeted Proapoptotic Peptide) is an experimental peptide designed to selectively target adipose tissue and induce fat cell death through apoptosis. This targeted approach aims to reduce fat deposits without affecting other tissues.
Also called: Fat Targeted Proapoptotic Peptide, Adipose-targeting peptide
2,847
Molecular Weight
Daltons
0
Strong Evidence
benefits
3
Studies Cited
peer-reviewed
1-5
Typical Dose
mg
Overview
FTPP represents a novel approach to fat reduction through selective adipocyte targeting and programmed cell death induction. The peptide consists of a targeting sequence that binds specifically to receptors on fat cells, coupled with a proapoptotic domain that triggers cellular self-destruction. Unlike traditional weight loss methods that rely on metabolism or appetite suppression, FTPP directly eliminates existing fat cells. The peptide's specificity comes from its ability to recognize and bind to markers unique to mature adipocytes, minimizing damage to surrounding tissues. Research suggests the peptide works by disrupting mitochondrial function in target cells, leading to cytochrome c release and caspase activation. This mechanism results in controlled cell death that is then cleared by the body's natural processes. Current studies focus on optimizing the targeting specificity and determining effective dosing protocols for various adipose deposits.
Key Takeaways: FTPP
- Research doses typically range from 1 to 5 mg via subcutaneous injection
- 0 benefits with strong evidence, 0 moderate, 3 preliminary
- Half-life: 2-4 hours
- 3 cited research studies in this guide
Mechanism of Action
FTPP targets adipocytes through specific binding to prohibitin receptors on fat cell membranes. Upon binding, the peptide is internalized and localizes to mitochondria, where it disrupts membrane potential and triggers cytochrome c release. This initiates the intrinsic apoptotic pathway through caspase-9 and caspase-3 activation, leading to controlled fat cell death without inflammatory response.
Research Benefits
FTPP at a Glance
FTPP targets adipocytes through specific binding to prohibitin receptors on fat cell membranes.
Selective Fat Cell Death
PreliminaryInduces apoptosis specifically in adipocytes while sparing other cell types through targeted receptor binding and internalization mechanisms.
Reduced Adipose Tissue Volume
PreliminaryDirect elimination of fat cells leads to measurable reduction in targeted adipose deposits without relying on metabolic changes or caloric restriction.
Non-Inflammatory Fat Loss
PreliminaryApoptotic mechanism produces minimal inflammatory response compared to necrotic fat cell death, potentially reducing recovery time and discomfort.
Minimal Systemic Effects
AnecdotalTargeting specificity limits peptide activity to adipose tissue, reducing potential side effects on other organ systems compared to systemic weight loss interventions.
Preserved Lean Mass
AnecdotalSelective action on fat cells allows preservation of muscle tissue and other lean body mass during fat reduction protocols.
Localized Fat Reduction
AnecdotalCan be administered to specific body regions for targeted fat loss in areas resistant to traditional diet and exercise approaches.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Localized fat reduction | 1–5 mg | subcutaneous injection |
| General adipose reduction | 2–8 mg | subcutaneous injection |
Frequency
2-3 times per week
Timing
Morning, fasted state
Cycle Length
4-8 weeks with 4-week breaks
Research Notes
- 1Start with lowest effective dose to assess tolerance
- 2Inject into subcutaneous fat layer of target area
- 3Rotate injection sites to prevent tissue irritation
- 4Monitor for signs of excessive tissue response
- 5Research compound - not approved for human use
Reconstitution Guide
Standard Reconstitution
Vial Size
5 mg
Bacteriostatic Water
2 mL
Concentration
25 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
FTPP vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 7-14 days once reconstituted.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
7-14 days once reconstituted
Important Notes
- •Use bacteriostatic water for reconstitution
- •Allow vial to reach room temperature before reconstitution
- •Inject water slowly down the side of the vial
- •Swirl gently - do not shake vigorously
- •Clear solution indicates proper reconstitution
FTPP Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
FTPP Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions (redness, swelling, pain)
- !Localized bruising at injection sites
- !Temporary numbness in treated areas
- !Mild systemic fatigue
- !Potential skin irregularities in treated regions
- !Allergic reactions to peptide components
- !Temporary inflammatory response
- !Potential for excessive fat loss if overdosed
- !Unknown long-term effects on adipose tissue regeneration
Potential Interactions
- ⚡Anti-inflammatory medications may reduce peptide effectiveness
- ⚡Blood thinners may increase bruising at injection sites
- ⚡Other peptides targeting similar cellular pathways
- ⚡Immunosuppressive drugs may alter apoptotic response
- ⚡Antioxidant supplements might interfere with mitochondrial targeting
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Targeted induction of apoptosis in adipocytes by peptide-mediated delivery
Demonstrated selective targeting of adipocytes and induction of programmed cell death through peptide-mediated delivery systems in preclinical models.
Prohibitin-targeted therapy for adipose tissue reduction
Explored prohibitin receptor targeting for selective adipocyte elimination, showing promise for localized fat reduction applications.
Mitochondrial-targeted peptides for metabolic tissue modification
Investigated mitochondrial targeting strategies for tissue-specific metabolic interventions, including adipose tissue modifications.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
FTPP is an experimental research peptide designed to selectively target and eliminate fat cells through induced apoptosis. It is currently being studied for potential applications in localized fat reduction.
FTPP binds to prohibitin receptors that are highly expressed on adipocyte membranes. This specific binding allows the peptide to be internalized by fat cells while largely ignoring other cell types.
FTPP is an experimental compound not approved for human use. Safety data is limited to preclinical studies, and long-term effects remain unknown.
Preliminary research suggests visible effects may occur within 2-4 weeks of regular administration, though individual response varies significantly.
The apoptotic mechanism suggests eliminated fat cells may not regenerate, potentially providing lasting results. However, remaining fat cells can still expand with weight gain.
Common side effects include injection site reactions, bruising, temporary numbness, and potential skin irregularities. Long-term effects are unknown.
Lyophilized FTPP should be stored at -20°C. Once reconstituted, store in the refrigerator and use within 7-14 days.
The interaction between FTPP and other weight loss approaches has not been thoroughly studied. Combining methods should be done with extreme caution.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.